Company Filing History:
Years Active: 1991-1997
Title: Mitsutaka Yoshida: Innovator in Therapeutic Compounds
Introduction
Mitsutaka Yoshida is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of therapeutic compounds, particularly in the development of anti-oxidative agents. With a total of 5 patents to his name, Yoshida's work is recognized for its potential impact on ischemic diseases.
Latest Patents
Yoshida's latest patents include the innovative 4-alkoxy-2, 6-di-t-butylphenol derivatives. These compounds are represented by a specific general formula, where R.sup.1 can be a hydrogen atom or an acyl group, and R.sup.2 is a lower alkyl group. The compounds exhibit highly selective anti-oxidative activity, making them useful as therapeutics for ischemic diseases such as arteriosclerosis and myocardial infarction.
Career Highlights
Yoshida is currently associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company. His work focuses on the synthesis and application of novel compounds that can address critical health issues. His innovative approach has garnered attention in the scientific community.
Collaborations
Yoshida has collaborated with notable colleagues, including Kunio Tamura and Yoshiaki Kato. These partnerships have contributed to the advancement of research and development in therapeutic compounds.
Conclusion
Mitsutaka Yoshida's contributions to the field of therapeutic compounds highlight his role as an influential inventor. His innovative work continues to pave the way for advancements in treatments for ischemic diseases.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.